Compare GTEC & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTEC | BIVI |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | 340 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 13.3M |
| IPO Year | N/A | 2013 |
| Metric | GTEC | BIVI |
|---|---|---|
| Price | $0.54 | $2.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 72.8K | ★ 177.7K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.62 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $1.06 |
| 52 Week High | $2.06 | $9.09 |
| Indicator | GTEC | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 40.17 | 64.39 |
| Support Level | $0.52 | $1.22 |
| Resistance Level | $0.73 | N/A |
| Average True Range (ATR) | 0.04 | 0.22 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 9.73 | 80.36 |
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.